Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam versus propofol for perioperative respiratory adverse events in children undergoing tonsillectomy and/or adenoidectomy
ChiCTR2600134184Phase 4Not yet recruiting
- Sponsor
- Children's Hospital of Chongqing Medical University
- Start
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in Tonsillar hyperplasia and adenoidal hypertrophy comparing Propofol group with Remimazolam group (2 arms). Primary endpoint: Incidence of perioperative respiratory adverse events. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
remimazolampropofol
03
Conditions
Tonsillar hyperplasiaadenoidal hypertrophy
Beyond the preview
Go deeper on ChiCTR2600134184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134184.